Mechanism-based pharmacokinetic/pharmacodynamic modeling of the effects of sitagliptin on DPP-4 activity, insulin and glucose in diabetic rats

doi:10.5246/jcps.2018.06.038

Abstract

Abstract:

Dipeptidyl peptidase-4 (DPP-4) inhibitors exert their antihyperglycemic effects through repressing inactivation of certain incretin hormones and thus increasing insulin secretion and controlling glucose level. In this study, the plasma concentrations of sitagliptin, a potent DPP-4 inhibitor, after a single oral dose of 300 mg/kg in streptozotocin-induced type 2 diabetic rats were determined by HPLC. A one-compartment pharmacokinetic (PK) model with first order absorption was developed to describe the PK profile of sitagliptin, and the drug concentrations at the doses given in the pharmacodynamic (PD) study were simulated accordingly. The dynamic changes in DPP-4 activity, insulin concentration and blood glucose level in diabetic rats at doses of 1, 5 and 10 mg/kg were measured, and a mechanism-based PK/PD model was established subsequently. In this model, the inhibitory effect of sitagliptin on DPP-4 activity was demonstrated using the Hill’s function with direct link, and the downstream increase in insulin secretion and inhibition of glucose production were characterized using indirect response (IDR) models. This model interpreted the mechanism of antihyperglycemic action of sitagliptin, and may be modified and applied to other species or other agents in this class.

Key words: Sitagliptin, Type 2 diabetes mellitus, Rats, DPP-4, Insulin, Glucose, Mechanism-based pharmacokinetic/pharmacodynamic model

CLC Number:

R969.1

Supporting:

Ye Yao, Xiangfei Jiu, Siyuan Wang, Wei Lu, Tianyan Zhou. Mechanism-based pharmacokinetic/pharmacodynamic modeling of the effects of sitagliptin on DPP-4 activity, insulin and glucose in diabetic rats[J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(6): 371-382.

References

[1] International Diabetes Federation. IDF Diabetes Atlas 8th Edition. 2017, 43-46. This article can be found online at https://www.idf.org/e-library/epidemiology-research/diabetes-atlas.html.

[2] DeFronzo, R.A.; Ferrannini, E.; Groop, L.; Henry, R.R.; Herman, W.H.; Holst, J.J.; Hu, F.B.; Kahn, C.R.; Raz, I.; Shulman, G.I.; Simonson, D.C.; Testa, M.A.; Weiss, R. Type 2 Diabetes Mellitus. Nat. Rev. Dis. Primers. 2015, 1, 15019.

[3] Drucker, D.J.; Nauck, M.A. The Incretin System: Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes. Lancet. 2006, 368, 1696-1705.

[4] Plosker, G.L. Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs. 2014, 74, 223-242.

[5] Herman, G.A.; Bergman, A.; Stevens, C.; Kotey, P.; Yi, B.; Zhao, P.; Dietrich, B.; Golor, G.; Schrodter, A.; Keymeulen, B.; Lasseter, K.C.; Kipnes, M.S.; Snyder, K.; Hilliard, D.; Tanen, M.; Cilissen, C.; De Smet, M.; de Lepeleire, I.; Van Dyck, K.; Wang, A.Q.; Zeng, W.; Davies, M.J.; Tanaka, W.; Holst, J.J.; Deacon, C.F.; Gottesdiener, K.M.; Wagner, J.A. Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2006, 91, 4612-4619.

[6] Langley, A.K.; Suffoletta, T.J.; Jennings, H.R. Dipeptidyl Peptidase IV Inhibitors and the Incretin System in Type 2 Diabetes Mellitus. Pharmacotherapy. 2007, 27, 1163-1180.

[7] Herman, G.A.; Stevens, C.; Van Dyck, K.; Bergman, A.; Yi, B.; De Smet, M.; Snyder, K.; Hilliard, D.; Tanen, M.; Tanaka, W.; Wang, A.Q.; Zeng, W.; Musson, D.; Winchell, G.; Davies, M.J.; Ramael, S.; Gottesdiener, K.M.; Wagner, J.A. Pharmacokinetics and Pharmacodynamics of Sitagliptin, an Inhibitor of Dipeptidyl Peptidase IV, in Healthy Subjects: Results from Two Randomized, Double-Blind, Placebo-Controlled Studies with Single Oral Doses. Clin. Pharmacol. Ther. 2005, 78, 675-688.

[8] Scheen, A.J. Pharmacokinetic and Pharmacodynamic Evaluation of Sitagliptin Plus Metformin. Expert Opin. Drug Metab. Toxicol. 2010, 6, 1265-1276.

[9] Agoram, B.M.; Martin, S.W.; van der Graaf, P.H. The Role of Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modelling in Translational Research of Biologics. Drug Discov. Today. 2007, 12, 1018-1024.

[10] Murai, K.; Katsuno, T.; Miyagawa, J.; Matsuo, T.; Ochi, F.; Tokuda, M.; Kusunoki, Y.; Miuchi, M.; Namba, M. Very Short-Term Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on the Secretion of Insulin, Glucagon, and Incretin Hormones in Japanese Patients with Type 2 Diabetes Mellitus: Analysis of Meal Tolerance Test Data. Drugs R. D. 2014, 14, 301-308.

[11] Iwamoto, Y.; Taniguchi, T.; Nonaka, K.; Okamoto, T.; Okuyama, K.; Arjona Ferreira, J.C.; Amatruda, J. Dose-Ranging Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus. Endocr. J. 2010, 57, 383-394.

[12] Zambrowicz, B.; Ding, Z.M.; Ogbaa, I.; Frazier, K.; Banks, P.; Turnage, A.; Freiman, J.; Smith, M.; Ruff, D.; Sands, A.; Powell, D. Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes. Clin. Ther. 2013, 35, 273-285 e7.

[13] Stepensky, D.; Friedman, M.; Raz, I.; Hoffman, A. Pharmacokinetic-Pharmacodynamic Analysis of the Glucose-Lowering Effect of Metformin in Diabetic Rats Reveals First-Pass Pharmacodynamic Effect. Drug Metab. Dispos. 2002, 30, 861-868.

[14] Jiu, X.F.; Shang, D.W.; Chen, Y.; Li, X.G.; Wan, X.M.; Zhou, T.Y.; Lu, W. A High Performance Liquid Chromatography Method for the Quantitative Deter-mination Assay of Sitagliptin in Rat Plasma and Its Application in Pharmacokinetics Study. J. Chin. Pharm. Sci. 2011, 20, 63-69.

[15] Hill, A. The Possible Effects of the Aggregation of the Molecules of Haemoglobin on Its Dissociation Curves. J. Physiol. 1910, 40 (supplement), 1115-1121.

[16] Dayneka, N.L.; Garg, V.; Jusko, W.J. Comparison of Four Basic Models of Indirect Pharmacodynamic Responses. J. Pharmacokinet. Biopharm. 1993, 21, 457-478.

[17] Rizza, R.A.; Mandarino, L.J.; Gerich, J.E. Dose-Response Characteristics for Effects of Insulin on Production and Utilization of Glucose in Man. Am. J. Physiol. 1981, 240, E630-639.

[18] Beconi, M.G.; Reed, J.R.; Teffera, Y.; Xia, Y.Q.; Kochansky, C.J.; Liu, D.Q.; Xu, S.; Elmore, C.S.; Ciccotto, S.; Hora, D.F.; Stearns, R.A.; Vincent, S.H. Disposition of the Dipeptidyl Peptidase 4 Inhibitor Sitagliptin in Rats and Dogs. Drug Metab. Dispos. 2007, 35, 525-532.

[19] Bergman, A.; Mistry, G.C.; Luo, W.L.; Liu, Q.; Stone, J.; Wang, A.; Zeng, W.; Chen, L.; Dilzer, S.; Lasseter, K.; Herman, G.A.; Wagner, J.A.; Krishna, R. Dose-Proportionality of a Final Market Image Sitagliptin Formulation, an Oral Dipeptidyl Peptidase-4 Inhibitor, in Healthy Volunteers. Biopharm. Drug Dispos. 2007, 28, 307-313.

[20] Ceriello, A.; Sportiello, L.; Rafaniello, C.; Rossi, F. DPP-4 Inhibitors: Pharmacological Differences and Their Clinical Implications. Expert Opin. Drug Saf. 2014, 13, S57-68.

[21] Kim, B.H.; Kim, S.E.; Kang, D.; Lim, K.S.; Kim, J.R.; Jang, I.J.; Shin, S.G.; Yoon, S.H.; Cho, J.Y.; Yu, K.S. Pharmacokinetic-Pharmacodynamic Modelling of Biomarker Response to Sitagliptin in Healthy Volunteers. Basic Clin. Pharmacol. Toxicol. 2013, 113, 113-125.

[22] Li, X.G.; Li, L.; Zhou, X.; Chen, Y.; Ren, Y.P.; Zhou, T.Y.; Lu, W. Pharmacokinetic/Pharmacodynamic Studies on Exenatide in Diabetic Rats. Acta Pharmacol. Sin. 2012, 33, 1379-1386.

[23] Bergman, A.J.; Stevens, C.; Zhou, Y.; Yi, B.; Laethem, M.; De Smet, M.; Snyder, K.; Hilliard, D.; Tanaka, W.; Zeng, W.; Tanen, M.; Wang, A.Q.; Chen, L.; Winchell, G.; Davies, M.J.; Ramael, S.; Wagner, J.A.; Herman, G.A. Pharmacokinetic and Pharmacodynamic Properties of Multiple Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-IV Inhibitor: a Double-Blind, Randomized, Placebo-Controlled Study in Healthy Male Volunteers. Clin. Ther. 2006, 28, 55-72.

[24] Landersdorfer, C.B.; He, Y.L.; Jusko, W.J. Mechanism-Based Population Modelling of the Effects of Vildagliptin on GLP-1, Glucose and Insulin in Patients with Type 2 Diabetes. Br. J. Clin. Pharmacol. 2012, 73, 373-390.

[25] Gao, W.; Jusko, W.J. Modeling Disease Progression and Rosiglitazone Intervention in Type 2 Diabetic Goto-Kakizaki Rats. J. Pharmacol. Exp. Ther. 2012, 341, 617-625.